title: Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis.
abstract: OBJECTIVE
  To compare the administration of GnRH antagonist in gonadotropin intrauterine insemination (IUI) cycles with cycles where no intervention took place.
  
  
  METHODS
  Meta-analysis of published prospective randomized trials.
  
  
  METHODS
  Five hundred twenty-one patients who were administered a GnRH antagonist and 548 conservatively treated patients who served as control subjects were included in the meta-analysis.
  
  
  METHODS
  
  
  
  METHODS
  Prospective trials were retrieved from Medline and Cochrane Library (last update October 2006). Random effect analysis was used in this meta-analysis. Two independent reviewers performed data extraction.
  
  
  METHODS
  Clinical pregnancy rates.
  
  
  RESULTS
  Six comparisons were retrieved including 1,069 patients. Higher pregnancy rates were found in the randomized controlled trials (odds ratio [OR] 1.56, 95% confidence interval [CI] 1.05-2.33) when a GnRH antagonist was added to a gonadotropin superovulated IUI protocol. Early published studies with smaller sample sizes showed stronger associations (OR 2.31, 95% CI 1.15-4.63) than later studies (OR 1.32, 95% CI 0.79-2.23).
  
  
  CONCLUSIONS
  From the randomized controlled trials of this meta-analysis, it is clear that allowing for follicle growth and avoiding premature LH rise, increased pregnancy rates are observed with GnRH antagonist administration. A parallel trend for multiple pregnancy rates in the GnRH antagonist group was observed, although this did not reach statistical significance. The flexible regimen was widely used. This meta-analysis of early data might enhance further research in this direction.
authors.affiliation: Center for Reproductive Medicine, Dutch-Speaking Brussels Free University, Brussels, Belgium. kosmasioannis@gmail.com
authors.forename: Ioannis P
authors.initials: IP
authors.lastname: Kosmas
authors.forename: Athina
authors.initials: A
authors.lastname: Tatsioni
authors.forename: Efstratios M
authors.initials: EM
authors.lastname: Kolibianakis
authors.forename: Willem
authors.initials: W
authors.lastname: Verpoest
authors.forename: Herman
authors.initials: H
authors.lastname: Tournaye
authors.forename: Josiane
authors.initials: J
authors.lastname: Van der Elst
authors.forename: Paul
authors.initials: P
authors.lastname: Devroey
mesh_terms: D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors*; D006727:Hormone Antagonists / Q000008:administration & dosage*; D006801:Humans; D007315:Insemination, Artificial / Q000379:methods; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
chemical_list: D006727:Hormone Antagonists; D007987:Gonadotropin-Releasing Hormone; C061018:ganirelix; C062876:cetrorelix